Samantha Holden
Title | Associate Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-NEUR General Operations |
---|
Phone | 720/848-2080 |
---|
|
|
|
Title | Assoc Chair |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-NEUR General Operations |
---|
|
|
---|
|
Biography New York University, New York, NY | BS | 05/2006 | Neural Science | Stony Brook University School of Medicine, Stony Brook, NY | MD | 05/2010 | Medicine | University of Colorado, Aurora, CO | MS | 05/2018 | Clinical Science | Rush University Medical Center, Chicago, IL | | 06/2011 | Internal Medicine Internship | Rush University Medical Center, Chicago, IL | | 06/2014 | Neurology Residency | University of Colorado, Aurora, CO | | 06/2015 | Movement Disorders Fellowship | University of Colorado, Aurora, CO | | 06/2017 | Behavioral Neurology Fellowship |
Overview Bibliographic
-
Carlisle TC, Medina LD, Holden SK. Original research: initial development of a pragmatic tool to estimate cognitive decline risk focusing on potentially modifiable factors in Parkinson's disease. Front Neurosci. 2023; 17:1278817. PMID: 37942138.
-
Thaker AA, McConnell BV, Rogers DM, Carlson NE, Coughlan C, Jensen AM, Lopez-Paniagua D, Holden SK, Pressman PS, Pelak VS, Filley CM, Potter H, Solano DA, Heffernan KS, Bettcher BM. Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women. Brain Behav Immun. 2023 10; 113:124-135. PMID: 37394144.
-
Carlisle TC, Fought AJ, Olson KE, Lopez-Esquibel N, Simpson A, Medina LD, Holden SK. Original research: longitudinal evaluation of cognitively demanding daily function using performance-based functional assessment highlights heterogeneous trajectories in cognitive and functional abilities in people with Parkinson's disease. Front Neurosci. 2023; 17:1200347. PMID: 37434765.
-
Feuerstein J, Heffernan B, Holden SK, Sillau S, Berman BD. Social Cognition Deficits in Cervical Dystonia, but not Blepharospasm: Focal Dystonias Diverge. Mov Disord Clin Pract. 2023 Aug; 10(8):1231-1232. PMID: 37635782.
-
Holden SK, Bedenfield N, Taylor AS, Bayram E, Schwilk C, Fleisher J, Duda J, Shill H, Paulson HL, Stacy K, Wood J, Corsentino P, Sha SJ, Litvan I, Irwin DJ, Quinn JF, Goldman JG, Amodeo K, Taylor JP, Boeve BF, Armstrong MJ. Research Priorities of Individuals and Caregivers With Lewy Body Dementia: A Web-based Survey. Alzheimer Dis Assoc Disord. 2023 Jan-Mar 01; 37(1):50-58. PMID: 36821177.
-
Holden SK, Bettcher BM, Filley CM, Lopez-Paniagua D, Pelak VS. Posterior white matter integrity and self-reported posterior cortical symptoms using the Colorado Posterior Cortical Questionnaire. Front Neurol. 2023; 14:1072938. PMID: 36816576.
-
Chiu SY, Wyman-Chick KA, Ferman TJ, Bayram E, Holden SK, Choudhury P, Armstrong MJ. Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions. Parkinsonism Relat Disord. 2023 02; 107:105285. PMID: 36682958.
-
Wylie KP, Kluger BM, Medina LD, Holden SK, Kronberg E, Tregellas JR, Buard I. Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease. Eur J Neurosci. 2023 02; 57(3):511-526. PMID: 36516060.
-
Bayram E, Holden SK, Fullard M, Armstrong MJ. Race and Ethnicity in Lewy Body Dementia: A Narrative Review. J Alzheimers Dis. 2023; 94(3):861-878. PMID: 37355902.
-
Holden SK, Pelak VS, Sooy T, Heffernan KS, McConnell BV, Pressman PS, Bettcher BM. Development of the Colorado posterior cortical questionnaire within an Alzheimer's disease study cohort. J Clin Exp Neuropsychol. 2022 04; 44(3):226-236. PMID: 35913095.
-
Goldman JG, Holden SK. Cognitive Syndromes Associated With Movement Disorders. Continuum (Minneap Minn). 2022 06 01; 28(3):726-749. PMID: 35678400.
-
Pelak VS, Paez YM, Patnaik JL, Holden SK, Subramanian PS, Mathias MT, Mandava N, Lynch AM. An Exploratory Study to Investigate the Utility of Clinical Screening for Neurodegenerative Disease in Age-Related Eye Disease Research. J Neuroophthalmol. 2022 09 01; 42(3):346-352. PMID: 35483065.
-
Buard I, Lopez-Esquibel N, Carey FJ, Brown MS, Medina LD, Kronberg E, Martin CS, Rogers S, Holden SK, Greher MR, Kluger BM. Does Prefrontal Glutamate Index Cognitive Changes in Parkinson's Disease? Front Hum Neurosci. 2022; 16:809905. PMID: 35496064.
-
Kletenik I, Holden SK, Sillau SH, O'Connell N, MacGillivray L, Mack J, Haddock B, Ashworth Dirac M, David AS, Nicholson TR, Attaripour Isfahani SN, Maurer CW, Lidstone SC, Hallett M, LaFaver K, Berman BD, Stone J. Gender disparity and abuse in functional movement disorders: a multi-center case-control study. J Neurol. 2022 Jun; 269(6):3258-3263. PMID: 35098346.
-
Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, Lemstra AW, Shaw LM, Teunissen CE, Zetterberg H, Taylor AS, Graham TC, Boeve BF, Gomperts SN, Graff-Radford NR, Moussa C, Poston KL, Rosenthal LS, Sabbagh MN, Walsh RR, Weber MT, Armstrong MJ, Bang JA, Bozoki AC, Domoto-Reilly K, Duda JE, Fleisher JE, Galasko DR, Galvin JE, Goldman JG, Holden SK, Honig LS, Huddleston DE, Leverenz JB, Litvan I, Manning CA, Marder KS, Pantelyat AY, Pelak VS, Scharre DW, Sha SJ, Shill HA, Mari Z, Quinn JF, Irwin DJ. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Front Neurol. 2021; 12:805135. PMID: 35173668.
-
Holden SK, Domen CH, Sillau S, Liu Y, Leehey MA. Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson's Disease. Mov Disord Clin Pract. 2022 Apr; 9(3):340-350. PMID: 35392299.
-
Simon OB, Rojas DC, Ghosh D, Yang X, Rogers SE, Martin CS, Holden SK, Kluger BM, Buard I. Profiling Parkinson's disease cognitive phenotypes via resting-state magnetoencephalography. J Neurophysiol. 2022 01 01; 127(1):279-289. PMID: 34936515.
-
Simon OB, Buard I, Rojas DC, Holden SK, Kluger BM, Ghosh D. A novel approach to understanding Parkinsonian cognitive decline using minimum spanning trees, edge cutting, and magnetoencephalography. Sci Rep. 2021 10 05; 11(1):19704. PMID: 34611218.
-
Buard I, Lattanzio L, Stewart R, Thompson S, Sjoberg K, Hookstadt K, Morrow M, Holden SK, Sillau S, Thaut M, Kluger B. Randomized controlled trial of neurologic music therapy in Parkinson's disease: research rehabilitation protocols for mechanistic and clinical investigations. Trials. 2021 Aug 28; 22(1):577. PMID: 34454592.
-
Lattanzio L, Seames A, Holden SK, Buard I. The emergent relationship between temporoparietal junction and anosognosia in Alzheimer's disease. J Neurosci Res. 2021 09; 99(9):2091-2096. PMID: 34131953.
-
Macchi ZA, Kletenik I, Olvera C, Holden SK. Psychiatric Comorbidities in Functional Movement Disorders: A Retrospective Cohort Study. Mov Disord Clin Pract. 2021 Jul; 8(5):725-732. PMID: 34307745.
-
Medina LD, Heffernan K, Holden S, Simpson A, Bettcher BM. Neural correlates of daily function: A pilot study of the white matter retrogenesis hypothesis and three separate performance-based functional assessments. Neuropsychology. 2021 Jan; 35(1):103-110. PMID: 33393804.
-
Holden SK, Bettcher BM, Pelak VS. Update on posterior cortical atrophy. Curr Opin Neurol. 2020 02; 33(1):68-73. PMID: 31688098.
-
Holden SK, Sheffler J, Stewart R, Thompson S, Persson J, Finseth T, Sillau S, Kluger BM. Feasibility of Home-Based Neurologic Music Therapy for Behavioral and Psychological Symptoms of Dementia: A Pilot Study. J Music Ther. 2019 Aug 13; 56(3):265-286. PMID: 31346625.
-
Holden SK, Van Dok E, Pelak VS. Co-occurrence of Convergence Insufficiency and Cognitive Impairment in Parkinsonian Disorders: A Pilot Study. Front Neurol. 2019; 10:864. PMID: 31447772.
-
Holden SK, Koljack CE, Prizer LP, Sillau SH, Miyasaki JM, Kluger BM. Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison. Parkinsonism Relat Disord. 2019 08; 65:172-177. PMID: 31253494.
-
Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B. Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimers Res Ther. 2019 03 13; 11(1):23. PMID: 30867052.
-
Holden SK, Medina LD, Hoyt B, Sillau SH, Berman BD, Goldman JG, Weintraub D, Kluger BM. Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. Mov Disord. 2018 11; 33(11):1760-1768. PMID: 30306618.
-
Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP. Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Mov Disord. 2018 04; 33(4):503-510. PMID: 29488270.
-
Kluger BM, Persenaire MJ, Holden SK, Palmer LT, Redwine H, Berk J, Anderson CA, Filley CM, Kutner J, Miyasaki J, Carter J. Implementation issues relevant to outpatient neurology palliative care. Ann Palliat Med. 2018 Jul; 7(3):339-348. PMID: 29307208.
-
Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Mov Disord Clin Pract. 2018 Jan-Feb; 5(1):47-53. PMID: 29662921.
-
Holden SK, Hall DA . Non-Parkinsonian Movement Disorders. Ataxia. 2017; 68-79.
-
Holden S, Goldman JG . Encyclopedia of Mental Health. Parkinson's Disease. 2016.
-
Holden SK, Jones WE, Baker KA, Boersma IM, Kluger BM. Outcome measures for Parkinson's disease dementia: a systematic review. Mov Disord Clin Pract. 2016 Jan-Feb; 3(1):9-18. PMID: 26998505.
-
Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6. PMID: 25449653.
-
Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol. 2014 Mar; 16(3):281. PMID: 24464490.
-
Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9. PMID: 24123267.
-
Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the PPMI cohort. Movement Disorders Clinical Practice.
-
Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP. Movement Disorders. Evolution of diagnostic criteria and assessments for Parkinson’s Disease-Mild Cognitive Impairment.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2013 | 1 | 2014 | 2 | 2015 | 1 | 2016 | 1 | 2017 | 3 | 2018 | 2 | 2019 | 4 | 2020 | 1 | 2021 | 6 | 2022 | 7 | 2023 | 9 |
To return to the timeline, click here.
|
Holden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) Derived automatically from this person's publications. _
Co-Authors ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People in Profiles who have published with this person. _
Similar People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|